Doctify

Docplanner Group is a healthcare technology company that connects patients with doctors. The company offers a platform for patients to find doctors, book appointments, and manage health-related inquiries, while providing doctors with tools to manage their practice. Docplanner Group serves the healthcare sector, addressing the needs of patients, doctors, and clinics. It was founded in 2012 and is based in Warsaw, Poland.

Qunomedical operates within the healthcare and medical travel industry, connecting patients with healthcare providers for a variety of medical procedures. The company provides information to ensure quality care. It offers a patient management software called Qunosuite, which is designed to streamline processes in healthcare settings. Qunomedical was formerly known as Junomedical. It was founded in 2015 and is based in Berlin, Germany.

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

InterveXion Therapeutics is a privately held clinical-stage biotech company focused on developing therapies for methamphetamine use disorder. The company offers a range of treatments including short and long-acting monoclonal antibodies and vaccines designed to prevent methamphetamine from entering the central nervous system. InterveXion's lead product is in Phase 2 clinical development for treating methamphetamine use disorder and overdose, supported by grants from the National Institute on Drug Abuse. It was founded in 2002 and is based in Little Rock, Arkansas.

silicos aims to empower virtual screening for in silico drug discovery

Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.